[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-embolism-and-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-embolism-and-thrombosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,69,98,121,139,166,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643287","thrombectomy-in-pulmonary-embolism-100643287",false,"NCT07650435","Thrombectomy in Pulmonary Embolism","Prospective Observational Study to Evaluate the Use of Computer-Aided Vacuum Thrombectomy Within the Context of Intermediate and High-Risk Pulmonary Embolism","TiPE","Inclusion Criteria:\n\n* Clinical signs and symptoms consistent with acute pulmonary embolism with duration of 14 days or less\n* Patients who present with computed tomography confirmed pulmonary embolism\n* Defined as intermediate or high-risk pulmonary embolism (according to European Society of Cardiology guidelines)\n* Date of computed tomography imaging from within a two-year period\n* Patient is greater than or equal to 18 years of age\n* Informed consent obtained\n* Evidence of cardiac dysfunction (either biochemical or imaging features of right heart strain)\n\nExclusion Criteria:\n\n* Known serious, uncontrolled sensitivity to radiographic agents\n* Computed tomography not available to evaluate pulmonary embolism\n* Low-risk pulmonary embolism as defined by European Society of Cardiology guidelines\n* Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational\n* Other medical, social, or psychological conditions that, in the opinion of the investigator, preclude the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study\n\nInclusion Criteria:\n\n1. Clinical signs and symptoms consistent with acute PE with duration of 14 days or less\n2. Patients who present with CT confirmed PE\n3. Defined as intermediate or high-risk PE (according to ESC guidelines1)\n4. Date of CT imaging from within a two-year period\n5. Patient is ≥ 18 years of age\n6. Informed consent obtained\n7. Evidence of cardiac dysfunction (Either biochemical or imaging features of RHS)\n\nExclusion Criteria:\n\n* 1\\. Known serious, uncontrolled sensitivity to radiographic agents 2. CT not available to evaluate PE 3. Low Risk PE as defined by ESC guidelines1 4. Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies 5. Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","Pulmonary embolism is a blood clot on the lung, which can cause death or significant reduced quality of life. Sucking the clot out with a special tube (catheter) is a relatively new procedure that can be performed but doesn't have the data required to properly support its use in some patients. We know this procedure works in patients who have no other options and would almost certainly die without intervention. We currently don't know how well this procedure is tolerated, how well it works and what its complications are in patients who are moderately to severely unwell. The National Institute of Clinical Excellence (NICE), an advisory body, suggests more data is required to support its use in patients who are sick or very sick. This registry aims to support this growing evidence base to workout if the treatment is effective and the associated risks that come with using it. We are collecting data about this procedure and other treatments patients get offered to better inform clinicians and researchers.",[25],"Pulmonary Embolism and Thrombosis",[27,28],"PE","Thrombectomy","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2026-05-11",{"date":37,"type":21},"2029-12-11",{"name":39,"class":40},"University Hospital Plymouth NHS Trust","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100637098","assessment-of-pulmonary-perfusion-and-hemodynamic-measurements-by-electrical-impedance-tomography-in-patients-undergoing-pulmonary-thromboendarterectomy-100637098","NCT07577700","Assessment of Pulmonary Perfusion and Hemodynamic Measurements by Electrical Impedance Tomography in Patients Undergoing Pulmonary Thromboendarterectomy.","Inclusion Criteria:\n\n\\- Patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) followed at the Pulmonology Service of InCor-HCFMUSP and scheduled for pulmonary thromboendarterectomy at InCor-FMUSP.\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy\n* Structural heart disease (atrial septal defect, ventricular septal defect, or valvular heart disease)\n* Cardiac arrhythmias\n* Use of a cardiac pacemaker or other implantable electronic device\n* Skin lesions on the thoracic region at the site of EIT electrode belt placement\n* Absence of central venous access on the day of the preoperative protocol evaluation\n* Difficulty understanding the procedures to be performed\n* Refusal to participate in the study (non-signing of the Informed Consent Form)\n* Refusal by the attending medical team",{"count":49,"type":21},36,"INTERVENTIONAL",[52],"NA","Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition in which old blood clots block the blood vessels in the lungs, making it harder for the heart to pump blood through the lungs. Surgery called pulmonary thromboendarterectomy can remove these clots and improve blood flow, but doctors need reliable ways to evaluate lung blood flow before and after surgery.\n\nThis study will evaluate a bedside imaging method called electrical impedance tomography (EIT), which can measure how blood flows through different regions of the lungs without radiation or invasive procedures. Patients undergoing surgery for CTEPH will be monitored with EIT before and after surgery, and the results will be compared with standard lung perfusion imaging.\n\nThe goal of this study is to determine whether EIT can provide useful information about lung blood flow and changes after surgery, and whether it could serve as a complementary bedside tool to help monitor patients with CTEPH.",[55,25],"Pulmonary Thromboendarterectomy",[57,58,59,60],"Pulmonary Perfusion","Electrical Impedance Tomography (EIT)","Cardiac Output","Resistência Vascular Pulmonar","2026-05-04",{"date":35,"type":33},{"date":64,"type":33},"2025-02-25",{"date":66,"type":21},"2026-12",{"name":68,"class":40},"University of Sao Paulo General Hospital",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":50,"phases":78,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100584221","early-phase-1-apixaban-in-thrombocytopenia-100584221","NCT06886516","Apixaban in Thrombocytopenia","ADAPTiON: Apixaban Dose Adjustment in Patient With Thrombocytopenia in ONcology","Inclusion Criteria:\n\n* Active malignancy defined as histologically confirmed diagnosis within last 6 months or received any cancer directed therapy within the last 6 months.\n* Radiologically confirmed newly diagnosed symptomatic deep vein thrombosis or pulmonary embolism within 28 days of enrollment. Includes proximal lower-limb DVT or symptomatic PE. Upper extremity or catheter-associated thrombosis will be included, as will distal lower extremity DVTs.\n* Platelet count \\\u003C 75,000\u002Fml (prior to platelet transfusion) within 28 days of VTE diagnosis.\n* Platelet count responsive to transfusion if previously administered (defined as an average platelet increase of at least 10,000\u002Fml over the last 3 transfusions.\n* No evidence of active hemorrhage.\n* No recent history of major hemorrhage (requiring transfusion, hospitalization or intervention) within the last 12 months.\n* No known brain metastases.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of apixaban in participants \\\u003C18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.\n* ECOG performance status ≤2\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Total bilirubin ≤ institutional upper limit of normal (ULN)\n  * AST(SGOT)\u002FALT(SGPT) ≤3 × institutional ULN\n  * Glomerular filtration rate (GFR) ≥25 mL\u002Fmin\u002F1.73\u002Fm2\n* Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* The effects of apixaban on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of apixaban administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who are receiving any other investigational agents.\n* Participants who have had a thrombectomy, insertion of a caval filter, or require a fibrinolytic agent.\n* Participants that have index events with severe clot burden defined as bilateral proximal lower extremity deep vein thrombosis and saddle embolism or pulmonary embolism with hemodynamic compromise.\n* Participants with acute myeloid leukemia or myelodysplastic syndrome or who are undergoing or have undergone allogeneic stem cell transplant.\n* Participants with luminal gastrointestinal malignancy or genitourinary cancer.\n* Presence of known or prior brain metastasis, given the increased risk of life-threatening intracranial hemorrhage with anticoagulant use. While screening for brain metastases is not standard of care in this population, investigators may obtain brain imaging if clinically indicated prior to initiation of anticoagulation. Imaging is not mandated in order to participate in this study.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to apixaban.\n* Participants receiving any medications or substances that are inhibitors or inducers of CYP3A\u002FP-gp are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.\n* Participants on aspirin (\\>100 mg\u002Fday), dual antiplatelet therapy, or receiving chronic treatment with NSAIDS\n* Participants with uncontrolled intercurrent illness.\n* Participants at high risk of bleeding such as:\n\n  * Unresected luminal\u002Fmucosal GI and GU cancers\n  * Active gastric or duodenal cancer\n  * History of major bleeding (based on ISTH criteria) in the past 12 months\n  * Any prior history of Intracranial hemorrhage (microhemorrhage is not included)\n  * Clinical or laboratory concern for ongoing DIC (prolonged PT\u002FAPTT or low fibrinogen)\n* Severe renal disease (CKD Stage IV or higher) or liver disease (Child Pugh B\u002FC)\n* Participants with pre-planned major surgery within the study period\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because apixaban has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with apixaban, breastfeeding should be discontinued if the mother is treated with apixaban.\n* Participant must be able to swallow pills.",{"count":77,"type":21},30,[79],"EARLY_PHASE1","This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes.\n\nThe name of the study drug involved in this study is:\n\n-Apixiban (a type of anticoagulant)",[82,25,83,84],"Deep Vein Thrombosis","Thrombocytopenia","Recurrent Venous Thromboembolism",[86,82,87,83,88,84],"Venous Thromboembolism","Pulmonary Embolism","Thromboembolism","2026-04-10",{"date":91,"type":33},"2026-04-15",{"date":93,"type":33},"2025-02-28",{"date":95,"type":21},"2029-07-01",{"name":97,"class":40},"Rushad Patell",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100476310","adverse-outcome-of-acute-pulmonary-embolism-by-artificial-intelligence-system-based-on-ct-pulmonary-angiography-100476310","NCT05482269","Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography","Prediction of Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography","PEAICTPA","Inclusion Criteria:\n\n* age of ≥ 18 years and a pulmonary embolism diagnosis based on CT pulmonary angiography\n\nExclusion Criteria:\n\n* pregnancy\n* reception of reperfusion treatment before admission\n* missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.",{"count":20,"type":21},"The investigators aim to build a predictive tool for Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography.",[25,109,110],"Deterioration, Clinical","Artificial Intelligence",[25,109,110],"2026-03-08",{"date":114,"type":33},"2026-03-11",{"date":116,"type":33},"2011-01-01",{"date":118,"type":21},"2026-12-31",{"name":120,"class":40},"Shengjing Hospital",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":130,"studyType":22,"phases":4,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":41},"100446848","a-predictive-tool-for-predicting-adverse-outcomes-in-acute-pulmonary-embolism-patients-using-ctpa-100446848","NCT05098769","A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.","A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using Parameters Obtained by Computed Tomographic Pulmonary Angiography.","Inclusion Criteria:\n\n* age of ≥ 18 years and a PE diagnosis based on CT pulmonary angiography\n\nExclusion Criteria:\n\n* pregnancy\n* reception of reperfusion treatment before admission\n* missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.",{"count":129,"type":21},300,"30 Days","This study collected clinical, laboratory, and CT parameters of acute patients with acute pulmonary embolism from admission to predict adverse outcomes within 30 days after admission into hospital.",[25,109],[25,109],{"date":114,"type":33},{"date":136,"type":33},"2021-01-18",{"date":118,"type":21},{"name":120,"class":40},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":147,"studyType":22,"phases":4,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":41},"100542868","registry-of-catheter-intervention-in-pulmonary-embolism-100542868","NCT06348459","Registry of Catheter Intervention in Pulmonary Embolism","RiTEP","Inclusion Criteria:\n\n* adult patients (aged 18 years old or older)\n* confirmed diagnosis of acute PE (on computed tomography or echocardiogram plus pulmonary angiography)\n* high-risk PE or intermediate-high risk according to ESC risk stratification in the 2019 guidelines (briefly, elevated cardiac biomarkers \\[troponin or N-terminal pro-B-type natriuretic peptide\\], and right ventricle to left ventricle ratio \\> 0.9 \\[on computed tomography or echocardiogram\\], and PE severity index III to IV or simplified PE severity index=1\n* eligibility for catheter-directed intervention\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of PE\n* undefined risk stratification, and\n* PE with uncertain chronology or beyond seven days of symptom initiation.",{"count":129,"type":21},"2 Years","Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study. The registry recruits a series of consecutive patients admitted for moderate-high risk or high-risk pulmonary embolism (according to 2019 European Society of Cardiology guidelines) treated invasively. This study aims to describe the acute management of the safety and effectiveness of different percutaneous interventions for acute pulmonary embolism.",[87,150,151,25,152],"Pulmonary Embolism Acute Massive","Pulmonary Embolism Acute","Pulmonary Thromboembolisms",[154,155,156],"Aspiration Thrombectomy","Percutaneous Aspiration Thrombectomy","Local Thrombolysis","2025-04-23",{"date":159,"type":33},"2025-04-25",{"date":161,"type":33},"2018-09-18",{"date":163,"type":21},"2030-12-31",{"name":165,"class":40},"Hospital San Carlos, Madrid",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":50,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":41},"100520013","compative-study-of-pe-in-thrombosed-avf-after-balloon-thrombectomy-vs-thromboaspiration-100520013","NCT06051032","Compative Study of PE in Thrombosed AVF After Balloon Thrombectomy Vs. Thromboaspiration.","Prospective Randomized Comparative Study on the Incidence of Pulmonary Emboembolism (PE) After Endovascular Treatment of Thrombosed Dialysis Arterio Venous Fistulas (AVF): Balloon Thrombectomy Versus Thromboaspiration Systems.","Inclusion Criteria:\n\n* Patients with acute thrombosis (\\\u003C 10 days) of native or prosthetic AVF.\n\nExclusion Criteria:\n\n* Known pulmonary hypertension.\n* Severe pulmonary disease.\n* Low cardiopulmonary reserve.\n* Recent creation of vascular access.\n* Known right left shunt.\n* Access infection.\n* Allergy to iodinated contrast.\n* Patients under 18 years old.",{"count":174,"type":21},60,[52],"The goal of this multicentric clinical trial is to compare the incidence of pulmonary thromboembolism (PTE), assessed through AngioCT, in the endovascular treatment of acute thrombosis in native and prosthetic arteriovenous fistulas (AVF). The main questions it aims to answer are:\n\n* What is the difference in the incidence of pulmonary thromboembolism (PTE) assessed by AngioCT in endovascular treatment of acute thrombosis of native and prosthetic arteriovenous fistulas using balloon thrombectomy versus thromboaspiration systems?\n* What is the primary patency rate of arteriovenous fistulas treated with balloon thrombectomy versus thromboaspiration systems?\n* What is the clinical success rate in the treatment of arteriovenous fistulas using balloon thrombectomy compared to thromboaspiration systems?\n* What are the costs associated with the different thrombectomy techniques in the treatment of arteriovenous fistulas?\n\nParticipants will be underwent to balloon thrombectomy versus thromboaspiration systems.\n\nResearchers will compare the patients treated with balloon thrombectomy and thromboaspiration systems to see if the incidence of PE is comparable and to evaluate the primary and secondary patency rates of both thrombectomy techniques, the clinical technical success rate, and the costs associated with each technique.",[25],"2025-01-24",{"date":180,"type":33},"2025-01-28",{"date":182,"type":33},"2023-07-21",{"date":184,"type":21},"2025-03",{"name":186,"class":40},"Instituto de Investigacion Sanitaria La Fe",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":50,"phases":198,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":41},"100533955","alerting-providers-at-patient-hospital-discharge-to-consider-prescribing-rivaroxaban-to-reduce-venous-thromboembolism-100533955","NCT06232551","Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism","eVTE (Electronic Venous Thromboembolism): A Cluster, Randomized, Step-wedge Type II Hybrid Study of an Alert Recommending Extended Duration Thromboprophylaxis for At-risk Discharging Medical Patients to Prevent VTE.","eVTE","Inclusion Criteria:\n\n* Discharging clinician must be in one of the following iCentra electronic health record (Cerner, Kansas City, MO) positions:\n\n  * Physician, nurse practitioner, or physician assistant hospitalist\n  * Physician internal medicine\n  * Physician family medicine\n* Patient age ≥ 18 years.\n* The encounter must be inpatient.\n* A signed hospital discharge order must be present.\n* eVTE target population criteria (increased venous thromboembolism risk, low bleeding risk) must be met\n\nExclusion Criteria:\n\n* Pregnant during encounter\n* Discharge order completed by ineligible clinician type\n* Exclude all cases where the patient is being actively prescribed and intended to be discharged on the following qualifying anticoagulant medications, regardless of dose form or dosing regimen (i.e., they have an active prescription for one of these medications):\n\n  * Apixaban\n  * Dabigatran\n  * Dalteparin\n  * Enoxaparin\n  * Edoxaban\n  * Betrixaban\n  * Fondaparinux\n  * Rivaroxaban\n  * Warfarin\n* Creatinine clearance \\\u003C30 milliliters\u002Fminute based on last-available eligible serum creatinine value preceding discharge\n\n  * Estimated creatine clearance based on actual body weight (preferred) ((140 - age years) \\* measured weight kilograms) \u002F (72.0 \\* serum creatine milligrams\u002Fdeciliter) (\\*0.85 if female)) = milliliters\u002Fminute\n  * If measured body weight not available, then based on ideal body weight ((140 - age years) \\* ideal body weight kilograms) \u002F (72.0 \\* serum creatine milligrams\u002Fdeciliter) (\\*0.85 if female)) = milliliters\u002Fminute","110 Years",{"count":197,"type":21},152000,[52],"A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal.\n\nThe purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low.\n\nThe pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.",[201,25,82,202],"Venous Thromboembolic Disease","Hospitalism",[204,205,206,207,208],"post-discharge","extended duration thromboprophylaxis","rivaroxaban","direct oral anticoagulant","medical patient","2024-07-15",{"date":211,"type":33},"2024-07-17",{"date":213,"type":33},"2024-06-01",{"date":215,"type":21},"2025-09-30",{"name":217,"class":40},"Scott C. Woller, MD"]